Trials / Unknown
UnknownNCT04966143
Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer
A Study of CLDN18.2 Chimeric Antigen Receptor T Cells in the Treatment of Advanced Pancreatic Cancer
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Longyao Biotechnology Inc., Ltd. · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
CLDN 18.2 chimeric antigen receptor T cells Clinical research plan for the treatment of recurrent or refractory pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LY011 | Targeting CLDN 18.2 Car-T injection |
Timeline
- Start date
- 2021-08-01
- Primary completion
- 2023-08-01
- Completion
- 2024-08-01
- First posted
- 2021-07-19
- Last updated
- 2021-07-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04966143. Inclusion in this directory is not an endorsement.